ERBB2 and breast carcinoma: Approximately 20% of breast cancers overexpress human epidermal growth factor receptor 2 (HER2), as determined by either 3+ staining by immunohistochemistry for the HER2 protein or evidence of HER2 gene amplification by fluorescence in situ hybridization.